SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001764013-24-000025
Filing Date
2024-02-12
Accepted
2024-02-12 07:02:27
Documents
15
Period of Report
2024-02-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K imvt-20240212.htm   iXBRL 8-K 27105
2 EX-99.1 exhibit9912024212.htm EX-99.1 83812
  Complete submission text file 0001764013-24-000025.txt   245486

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT imvt-20240212.xsd EX-101.SCH 1898
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT imvt-20240212_lab.xml EX-101.LAB 23834
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT imvt-20240212_pre.xml EX-101.PRE 12506
16 EXTRACTED XBRL INSTANCE DOCUMENT imvt-20240212_htm.xml XML 2712
Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

IRS No.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-38906 | Film No.: 24617340
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)